ArticleAlimentary pharmacology & therapeutics2022

A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II.

Marco Vincenzo Lenti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.